文献速递肿瘤 PET/CT神经核医学

[68Ga]Ga-NOTA-T4免疫PET显像评估实体瘤患者TROP2表达

[68Ga]Ga-NOTA-T4 ImmunoPET imaging for evaluating TROP2 expression in patients with solid tumors.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-05-09

前瞻性纳入26例实体瘤患者,评估[68Ga]Ga-NOTA-T4 PET/CT检测TROP2表达及诊断原发/转移灶的效用,并与[18F]FDG PET/CT直接比较。两种示踪剂均检出全部19个原发/复发肿瘤,[68Ga]Ga-NOTA-T4的SUVmax和TBR低于[18F]FDG,但检出2个[18F]FDG漏诊的脑转移灶。TROP2 TPS与[68Ga]Ga-NOTA-T4 SUVmax(r=0.85,P=0.002)及TBR(r=0.66,P=0.030)正相关。

要点

  • 26例实体瘤患者前瞻性研究,两种示踪剂均检出全部19个原发/复发肿瘤。
  • [68Ga]Ga-NOTA-T4的SUVmax和TBR低于[18F]FDG,但检出2个[18F]FDG漏诊的脑转移灶。
  • TROP2 TPS与[68Ga]Ga-NOTA-T4 SUVmax(r=0.85,P=0.002)及TBR(r=0.66,P=0.030)正相关。

核心结论

  • [68Ga]Ga-NOTA-T4 PET/CT是评估TROP2表达水平和诊断实体瘤有前景的无创工具,在某些特定情况下较[18F]FDG具有潜在优势。

研究设计与样本

  • 前瞻性纳入2023年10月至2024年8月接受[68Ga]Ga-NOTA-T4 PET/CT扫描的实体瘤患者,部分患者同时接受[18F]FDG PET/CT。
  • 共纳入26例患者(平均年龄63±10岁,女性13例)。
  • 用SUVmean量化生理器官摄取,通过视觉评估识别阳性病灶并用SUVmax和TBR量化,TBR为病灶SUVmax除以背景SUVmean(脑部病灶用脑背景,其他病灶用血池背景)。
  • 通过免疫组化肿瘤比例评分(IHC TPS)评估TROP2表达水平,分析两种示踪剂的生物分布、病灶可检测性及与TROP2的相关性。

主要发现

  • [68Ga]Ga-NOTA-T4在肾、胰腺、甲状腺和下颌下腺高摄取,在脑、肌肉和骨低摄取。
  • 两种示踪剂均成功检出全部19个原发/复发肿瘤。
  • [68Ga]Ga-NOTA-T4的SUVmax低于[18F]FDG(1.93 [1.36, 2.58] vs. 11.37 [6.45, 13.15],P < 0.001),TBR也低于[18F]FDG(2.83 [2.17, 3.74] vs. 6.95 [5.24, 11.27],P = 0.03)。
  • [68Ga]Ga-NOTA-T4识别的可疑转移灶较少,但检出2个[18F]FDG漏诊的脑转移灶。
  • TROP2 TPS与[68Ga]Ga-NOTA-T4 SUVmax正相关(r = 0.85,P = 0.002),与TBR正相关(r = 0.66,P = 0.030),而[18F]FDG未见显著相关性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Gallium-68 (68Ga)-labeled [68Ga]Ga-NOTA-T4 immuno-positron emission tomography (immunoPET) holds great promise as a non-invasive technique for visualizing the expression of trophoblast cell-surface antigen 2 (TROP2). This approach may potentially assist in making clinical decisions regarding TROP2-targeted therapies. The present study aims to evaluate the utility of [68Ga]Ga-NOTA-T4 PET/CT in detecting TROP2 expression levels, diagnosing primary tumors and metastatic lesions. Additionally, it conducts a direct comparison with fluorine-18-labeled fluorodeoxyglucose ([18F]FDG) PET/CT. METHODS: Participants with solid tumors who underwent [68Ga]Ga-NOTA-T4 PET/CT scans were prospectively recruited between October 2023 and August 2024. A subset of these participants also received [18F]FDG PET/CT. The uptake in physiological organs was quantified using the mean standardized uptake value (SUVmean). Positive lesions were identified through visual assessments and further quantified using the maximum standardized uptake value (SUVmax) and the target-to-background ratio (TBR). The TBR was calculated by dividing the SUVmax of the lesion by the SUVmean of the background, where the brain background was used for cerebral lesions and the blood pool for other lesions. TROP2 expression levels were evaluated via immunohistochemical (IHC) tumor proportion score (TPS). Biodistribution, lesion detectability, and the correlation with TROP2 were analyzed for both tracers using appropriate statistical methods. RESULTS: A total of 26 patients (mean age: 63 ± 10 years; 13 females) were included in the study. [68Ga]Ga-NOTA-T4 demonstrated high uptake in the kidneys, pancreas, thyroid, and submaxillary gland, while showing low uptake in the brain, muscle, and bone. Both tracers successfully detected all 19 primary/recurrent tumors. However, [68Ga]Ga-NOTA-T4 presented lower SUVmax and TBR compared to [18F]FDG (1.93 [1.36, 2.58] vs. 11.37 [6.45, 13.15], P < 0.001; 2.83 [2.17, 3.74] vs. 6.95 [5.24, 11.27], P = 0.03, respectively). [68Ga]Ga-NOTA-T4 identified fewer suspected metastases but detected two brain metastases that were missed by [18F]FDG. TROP2 TPS was positively correlated with [68Ga]Ga-NOTA-T4 SUVmax (r = 0.85, P = 0.002) and TBR (r = 0.66, P = 0.030), while no significant correlation was observed for [18F]FDG. CONCLUSION: [68Ga]Ga-NOTA-T4 PET/CT emerges as a promising non-invasive tool for assessing TROP2 expression levels and diagnosing solid tumors. In certain specific cases, it exhibits potential advantages over [18F]FDG.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Jiang D, Chu Z, Wu Y, et al. [68Ga]Ga-NOTA-T4 ImmunoPET imaging for evaluating TROP2 expression in patients with solid tumors. Eur J Nucl Med Mol Imaging. 2025. PMID: 40342104. doi:10.1007/s00259-025-07326-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。